SecBot SecBot

TMDX

TransMedics Group, Inc.
Nasdaq· Electromedical & Electrotherapeutic Apparatus· Inc. MA· CIK 0001756262 Healthcare & Medical Devices
$92.21 +0.83 (+0.91%)
Nov 16 4:00 PM ET · prev $91.38
Market cap
$3.2B
Mid cap
Consensus
Buy
74% Buy or better · 19 analysts
Median target
$110.00
+19% · range $70.00–125.00
1 year
−18.7%
from $113.40 · Nov 17
30 days
+28.8%
from $71.60
52-week range
$62.04–150.42
−39% from high · low May 14
Avg volume 20D
1.23M
Nov 6 spike 3.95M
Short interest
8.88M
≈25.6% of shares · +1.2%
Days to cover
10.2
at average volume
Insider net
−$1.8M
1 buyer · 5 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 1 exit
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $109.1K at an average $81.63. 5 insiders sold $1.9M. Price is 13% above their cost.

  • InstitutionsMIXED

    Q3 2026: 20 added (2 new), 25 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $69.9M.

  • AnalystsBULLISH

    14 of 19 rate it Buy or better. Median target $110.00 (+19%).

  • EstimatesFALLING

    Current-quarter EPS estimate $0.530 → $0.451 over 90 days. 2 up, 6 down in 30 days.

  • Short sellersSTEADY

    Short interest +1.2% to 8.88M shares. 10.2 days to cover, ≈25.6% of shares.

  • TrendUPTREND

    15% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 6.

Who's buying

13F· Q3 2026
2
new positions
1
exit
$69.9M
in new stakes · top 1 shown
FundMoveSharesValue
BARROW HANLEY MEWHINNEY & STRAUSS LLCNEW837,530$69.9M
BNP PARIBAS FINANCIAL MARKETSDOUBLED410,817$34.3M
PRINCIPAL FINANCIAL GROUP INCADD372,534$31.1M
BARCLAYS PLCADD332,599$27.8M
HRT FINANCIAL LPADD289,614$24.2M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD154,648$12.3M
CITIGROUP INCTRIM102,878$8.6M
Invesco Ltd.NEAR_EXIT93,696$7.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 74% rate it Buy or better
Strong Buy5Buy9Hold5Sell0Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +19%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026UBS
MAINTAIN
MAINTAINNeutral
Nov 6, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Nov 6, 2026Needham
MAINTAIN
MAINTAINBuy
Nov 6, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 13, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 7, 2026Barclays
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$109.1K
bought · 1 insider
$1.9M
sold · 5 insiders
+13.0%
vs their $81.63 cost
DateInsiderTypeValue
Nov 9, 2026
TOBIN JAMES R
Director
Nov 9, 2026
SELL$5.5K
Nov 9, 2026
TOBIN JAMES R
Director
Nov 9, 2026
SELL$379.9K
Oct 28, 2026
Araujo Fernando N.
See Remarks
Oct 28, 2026
AWARD34,419 sh
Oct 28, 2026
Araujo Fernando N.
See Remarks
Oct 28, 2026
AWARD22,969 sh
Sep 11, 2026
Weill David
Director
Sep 11, 2026
BUY$109.1K
Aug 17, 2026
TOBIN JAMES R
Director
Aug 17, 2026
GIFT18,000 sh
Jul 10, 2026
Corcoran Nicholas
See remarks
Jul 10, 2026
AWARD11,727 sh
Jul 10, 2026
Hernandez Gerardo
Chief Financial Officer
Jul 10, 2026
AWARD17,246 sh

Earnings setup

Estimates
$0.45
EPS estimate, this quarter
−15%
estimate change, 90 days
2↑ 6↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.45$0.34–$0.53-9.7%$202.8M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

4 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,877,506
shares short
+1.2%
vs prior settlement
10.2
days to cover
≈25.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Director James R. Tobin filed a Form 144 notice of intent to sell 4,059 shares of TransMedics Group, Inc. common…
144 · Impact 2/10
Nov 9, 2026 Insider
TOBIN JAMES R sold 59 shares
Director @ $93.96 ($5.5K)
Nov 9, 2026 Insider
TOBIN JAMES R sold 4,000 shares
Director @ $94.98 ($379.9K)
Nov 5, 2026 SEC
TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating consensus estimates of…
8-K · Impact 6/10
Nov 5, 2026 SEC
TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating consensus estimates of…
PRESS-RELEASE · Impact 6/10
Nov 5, 2026 Earnings
TransMedics Reports Third Quarter 2026 Financial Results
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Comp
Oct 28, 2026 Insider
Araujo Fernando N. was granted 34,419 shares
See Remarks
Sep 30, 2026 Inst.
BARROW HANLEY MEWHINNEY & · NEW
837,530 shares ($69.9M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings
TransMedics Reports Third Quarter 2026 Financial Results
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and…
Nov 5, 2026
Earnings result
TMDX Q3 2026 Earnings: EPS $0.51 (+71.3% vs est)
Oct 30, 2026
Press release
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is…
Oct 29, 2026
Press release
TransMedics to Present at Upcoming Investor Conferences
ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is…
Aug 31, 2026
Press release
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary…

SecBot reports

9 filings · 5 bullish · 0 bearish · 4 neutral
All TMDX filing & press-release reports (9)